Endpoints News

Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test
Endpoints News
Data have shown that Xipere confers significant benefit irrespective of the anatomical location of the uveitis (anterior, intermediate, posterior, or panuveitis), making it a strong competitor to Allergan's $AGN Ozurdex, which is approved only for
Presentation of Additional Analyses of Clearside's PEACHTREE Clinical Trial Data Further Supports Potential of …Nasdaq

all 139 news articles »